Dermatitis herpetiformis Duhring as one of the forms of gluten-associated pathology: a review of the literature and a description of a clinical case

This review presents information on the prevalence, pathogenesis, clinical manifestations, diagnosis and treatment of Duhring’s dermatitis herpetiformis. Although the disease was first clinically described in 1884 by the American dermatologist L.A. Duhring, the study of its pathogenesis and the search for prognostic markers of its occurrence continue. Against the background of a significant expansion of ideas about gluten-dependent diseases and conditions, views on the mechanisms of autoimmune skin damage in dermatitis herpetiformis are detailed. A strong association with hereditary predisposition through the major human leukocyte histocompatibility complex (HLA) DQ2 and DQ8, and a role of epidermal transglutaminase as a major autoantigen in dermatitis herpetiformis are shown. The hypotheses explaining the decline in the incidence of dermatitis herpetiformis in recent decades against the background of increased and more effective serological screening and the resulting earlier diagnosis of celiac disease are commented on. A typical clinical picture of dermatitis herpetiformis, in which erythematous papules, plaques, vesicles are seen, usually clustered on the flexural surfaces of the extremities. Secondary elements are erosions, excoriations and crusts due to rupture of blisters and due to scratching caused by intense itching. A generally favourable prognosis for life and disease is shown with a gluten-free diet and the use of dapsone, glucocorticoids and, if these are ineffective, immunosuppressants. The authors describe a clinical case of the disease in an adolescent girl with a typical clinical history and characteristic rashes on the extensor surfaces of the limbs. The authors show that drug therapy without a gluten-free diet cannot be considered effective, and that the diet for dermatitis herpetiformis, like that for celiac disease, is lifelong. The growing understanding of gluten-associated pathology, which includes dermatitis herpetiformis, in recent decades has led to an intensive search for diagnostic and prognostic markers, as well as the development of ways to correct this group of diseases, including those not related to the lifelong elimination of cereal prolamines.

1. Karyakina L.A., Kukushkina K.S. Skin markers of celiac disease. Medicine: Theory and Practice. 2019;4(1):114–119. (In Russ.) Available at: http://ojs3.gpmu.org/index.php/med-theory-and-practice/article/view/454/456.

2. Novikov Yu.A., Zaslavskiy D.V., Pravdina O.V., Zykova E.A., Lipatnikova A.S., Bolshakova E.S. et al. During’s herpetiform dermatitis in pediatric dermatology: issues of diagnostics and treatment. Pediatrician (St Petersburg). 2020;11(6):79–86. (In Russ.) https://doi.org/10.17816/PED11679-86.

3. Butov Yu.S., Skripkin Yu.K., Ivanov O.L. (eds.). Clinical dermatovenerology: national guidelines. Moscow: GEOTAR-Media; 2013. 896 p. (In Russ.) Available at: http://library.zsmu.edu.ua/cgi/irbis64r_14/fulltext/Dermatovenerologija/ButovJuS13_Dermat_Nacio_ruk.pdf.

4. Antiga E., Maglie R., Quintarelli L., Verdelli A., Bonciani D., Bonciolini V., Caproni M. Dermatitis Herpetiformis: Novel Perspectives. Front Immunol. 2019;10:1290. https://doi.org/10.3389/fimmu.2019.01290.

5. Bolotin D., Petronic-Rosic V. Dermatitis herpetiformis. Part I. Epidemiology, pathogenesis, and clinical presentation. J Am Acad Dermatol. 2011;64(6):1017–1024. https://doi.org/10.1016/j.jaad.2010.09.777.

6. Salmi T.T., Hervonen K., Kautiainen H., Collin P., Reunala T. Prevalence and incidence of dermatitis herpetiformis: a 40-year prospective study from Finland. Br J Dermatol. 2011;165(2):354–359. https://doi.org/10.1111/j.1365-2133.2011.10385.x.

7. Zhang F., Yang B., Lin Y., Chen S., Zhou G., Wang G. et al. Dermatitis herpetiformis in China: a report of 22 cases. J Eur Acad Dermatol Venereol. 2012;26(7):903–907. https://doi.org/10.1111/j.1468-3083.2011.04204.x.

8. Ohata C., Ishii N., Niizeki H., Shimomura Y., Furumura M., Inoko H. et al. Unique characteristics in Japanese dermatitis herpetiformis. Br J Dermatol. 2016;174(1):180–183. https://doi.org/10.1111/bjd.13965.

9. Tkachenko S.B., Teplyuk N.P., Allenova A.S., Lepekhova A.A. On the classification of bullous dermatoses. Russian Journal of Skin and Venereal Diseases. 2015;18(2):11–14. (In Russ.) Available at: https://rjsvd.com/1560-9588/article/view/36927.

10. West J., Fleming K.M., Tata L.J., Card T.R., Crooks C.J. Incidence and prevalence of celiac disease and dermatitis herpetiformis in the UK over two decades: population-based study. Am J Gastroenterol. 2014;109(5):757–768. https://doi.org/10.1038/ajg.2014.55.

11. Tlish M.M., Kuznetsova T.G., Naatyzh Zh.Yu., Tikeeva R.M. Polymorbidity: a view on combined pathology. Kuban Scientific Medical Bulletin. 2019;26(5):125–134. (In Russ.) https://doi.org/10.25207/1608-6228-2019-26-5-125-134.

12. Collin P., Salmi T.T., Hervonen K., Kaukinen K., Reunala T. Dermatitis herpetiformis: a cutaneous manifestation of coeliac disease. Ann Med. 2017;49(1):23–31. https://doi.org/10.1080/07853890.2016.1222450.

13. Svechnikova E.V., Marshani Z.B., Pyurveeva K.V. Clinical polymorphism of dermatitis herpetiformis and atopic dermatitis, as diseases associated with celiakia. Medical News of North Caucasus. 2020;15(1):61–64. (In Russ.) https://doi.org/10.14300/mnnc.2020.15013.

14. Alshiekh S., Zhao L.P., Lernmark Å., Geraghty D.E., Naluai Å.T., Agardh D. Different DRB1*03:01-DQB1*02:01 haplotypes confer different risk for celiac disease. HLA. 2017;90(2):95–101. https://doi.org/10.1111/tan.13065.

15. Black K.E., Murray J.A., David C.S. HLA-DQ determines the response to exogenous wheat proteins: a model of gluten sensitivity in transgenic knockout mice. J Immunol. 2002;169(10):5595–5600. https://doi.org/10.4049/jimmunol.169.10.5595.

16. Kárpáti S., Sárdy M., Németh K., Mayer B., Smyth N., Paulsson M., Traupe H. Transglutaminases in autoimmune and inherited skin diseases: The phenomena of epitope spreading and functional compensation. Exp Dermatol. 2018;27(8):807–814. https://doi.org/10.1111/exd.13449.

17. Eckert R.L., Sturniolo M.T., Broome A.M., Ruse M., Rorke E.A. Transglutaminase function in epidermis. J Invest Dermatol. 2005;124(3):481–492. https://doi.org/10.1111/j.0022-202X.2005.23627.x.

18. Jaskowski T.D., Hamblin T., Wilson A.R., Hill H.R., Book L.S., Meyer L.J. et al. IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis and pediatric celiac disease. J Invest Dermatol. 2009;129(11):2728–2730. https://doi.org/10.1038/jid.2009.142.

19. Görög A., Németh K., Kolev K., Zone J.J., Mayer B., Silló P. et al. Circulating Transglutaminase 3-Immunoglobulin A Immune Complexes in Dermatitis Herpetiformis. J Invest Dermatol. 2016;136(8):1729–1731. https://doi.org/10.1016/j.jid.2016.03.039.

20. Graeber M., Baker B.S., Garioch J.J., Valdimarsson H., Leonard J.N., Fry L. The role of cytokines in the generation of skin lesions in dermatitis herpetiformis. Br J Dermatol. 1993;129(5):530–532. https://doi.org/10.1111/j.1365-2133.1993.tb00479.x.

21. Bognár P., Görög A., Kárpáti S. High prevalence of cryofibrinogenaemia in dermatitis herpetiformis. J Eur Acad Dermatol Venereol. 2016;30(3):517–518. https://doi.org/10.1111/jdv.12913.

22. Rabenhorst A., Hartmann K. Interleukin-31: a novel diagnostic marker of allergic diseases. Curr Allergy Asthma Rep. 2014;14(4):423. https://doi.org/10.1007/s11882-014-0423-y.

23. Malek M., Gleń J., Rębała K., Kowalczyk A., Sobjanek M., Nowicki R. et al. Il-31 does not correlate to pruritus related to early stage cutaneous T-cell lymphomas but is involved in pathogenesis of the disease. Acta Derm Venereol. 2015;95(3):283–288. https://doi.org/10.2340/00015555-1958.

24. Korotkiy N.G., Narinskaya N.M., Belmer S.V. Cutaneous manifestations of the pathology of the digestive system. Lechaschi Vrach. 2014;(2):66. (In Russ.) Available at: https://www.lvrach.ru/2014/02/15435898.

25. Zone J.J. Skin manifestations of celiac disease. Gastroenterology. 2005;128(4 Suppl. 1):S87–S91. https://doi.org/10.1053/j.gastro.2005.02.026.

26. Reunala T., Salmi T.T., Hervonen K., Kaukinen K., Collin P. Dermatitis Herpetiformis: A Common Extraintestinal Manifestation of Coeliac Disease. Nutrients. 2018;10(5):602. https://doi.org/10.3390/nu10050602.

27. Pozdnyakova O.N., Nemchaninova O.B., Sokolovskaya A.V., Eryomina T.A., Osipenko M.F., Lykova S.G. et al. Extraintestinal (dermatological) manifestations of malabsorption syndrome and celiac disease. Experimental and Clinical Gastroenterology. 2020;(10):107–111. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-182-10-107-111.

28. Ruvinskaya G.R., Silantieva E.N., Anokhina A.V. The need for a multidisciplinary approach to the diagnosis and treatment procedures of isolated lesions of the oral mucosa in dermatitis herpetiformis Duhring. Russian Journal of Dentistry. 2020;24(2):99–103. (In Russ.) https://doi.org/10.17816/1728-2802-2020-24-2-99-103.

29. Nicolas M.E., Krause P.K., Gibson L.E., Murray J.A. Dermatitis herpetiformis. Int J Dermatol. 2003;42(8):588–600. https://doi.org/10.1046/j.1365-4362.2003.01804.x.

30. Mistry A., Mistry N. Persistent pruritic papulovesicles. Dermatitis herpetiformis. Am Fam Physician. 2014;90(6):407–408. Available at: https://www.aafp.org/afp/2014/0915/p407.html.

31. Hofmann S.C., Nashan D., Bruckner-Tuderman L. Petechiae on the fingertips as presenting symptom of dermatitis herpetiformis Duhring. J Eur Acad Dermatol Venereol. 2009;23(6):732–733. https://doi.org/10.1111/j.1468-3083.2009.03200.x.

32. Kern M., Kim K.H., Johnson G., Hawkins S.D., Wong H.K. Dermatitis herpetiformis presenting as pseudovasculitis. JAAD Case Rep. 2017;3(5):444–447. https://doi.org/10.1016/j.jdcr.2017.06.033.

33. Saito M., Böer A., Ishiko A., Nishikawa T. Atypical dermatitis herpetiformis: a Japanese case that presented with initial lesions mimicking prurigo pigmentosa. Clin Exp Dermatol. 2006;31(2):290–291. https://doi.org/10.1111/j.1365-2230.2005.02009.x.

34. Kolos Yu.V. Bullous pemphigoid and dermatitis herpetiformis Duhring: clinical picture, diagnosis, treatment. Recipe. 2014;(5):88–97. (In Russ.) Available at: https://www.bsmu.by/files/89b9f10fd79bfb0abb9b6713d41093a5/.

35. Teplyuk N.P., Belousova T.A., Grabovskaya O.V., Pyatilova P.M., Allenova A.S. Linear IgA-dependent bullous dermatosis. Russian Journal of Skin and Venereal Diseases. 2015;18(1):40–45. (In Russ.) https://doi.org/10.17816/dv36957.

36. Faina V., Paolino G., Bavastrelli M., Calvieri S., Grieco T. Classification of cutaneous manifestations in patients with nonceliac gluten sensitivity and wheat allergy. J Am Acad Dermatol. 2021;85(2):469–472. https://doi.org/10.1016/j.jaad.2017.12.013.

37. Katina M.A., Tikhonovskaya I.V. Subepidermal bullous dermatoses. Part I. Dermatitis herpetiformis Duhring, linear IGA-dependent bullous dermatosis. Vestnik of Vitebsk State Medical University. 2019;18(2):7–15. (In Russ.) https://doi.org/10.22263/2312-4156.2019.2.7.

38. Ziemer M., Pemler S., Simon J.C., Treudler R. Acantholytic variant of Duhring’s disease. J Dtsch Dermatol Ges. 2016;14(2):186–188. https://doi.org/10.1111/ddg.12746.

39. Hashimoto T., Tsuruta D., Yasukochi A., Imanishi H., Sekine H., Fujita T. et al. Granular C3 Dermatosis. Acta Derm Venereol. 2016;96(6):748–753. https://doi.org/10.2340/00015555-2379.

40. Bresler S.C., Granter S.R. Utility of direct immunofluorescence testing for IgA in patients with high and low clinical suspicion for dermatitis herpetiformis. Am J Clin Pathol. 2015;144(6):880–884. https://doi.org/10.1309/AJCPXIVSR6OZK1HU.

41. Huber C., Trüeb R.M., French L.E., Hafner J. Negative direct immunofluorescence and nonspecific histology do not exclude the diagnosis of dermatitis herpetiformis Duhring. Int J Dermatol. 2013;52(2):248–249. https://doi.org/10.1111/j.1365-4632.2011.04909.x.

42. Antiga E., Caproni M. The diagnosis and treatment of dermatitis herpetiformis. Clin Cosmet Investig Dermatol. 2015;8:257–265. https://doi.org/10.2147/CCID.S69127.

43. Salmi T.T., Kurppa K., Hervonen K., Laurila K., Collin P., Huhtala H. et al. Serum transglutaminase 3 antibodies correlate with age at celiac disease diagnosis. Dig Liver Dis. 2016;48(6):632–637. https://doi.org/10.1016/j.dld.2016.03.003.

44. Caproni M., Antiga E., Melani L., Fabbri P. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. J Eur Acad Dermatol Venereol. 2009;23(6):633–638. https://doi.org/10.1111/j.1468-3083.2009.03188.x.

45. Criado P.R., Criado R.F., Aoki V., Belda W. Jr, Halpern I., Landman G., Vasconcellos C. Dermatitis herpetiformis: relevance of the physical examination to diagnosis suspicion. Can Fam Physician. 2012;58(8):843–847. Available at: https://www.cfp.ca/content/58/8/843.long.

46. Bitkina O.A., Krivonogova P.L., Martusevich A.K., Panteleeva G.A. Physicochemical parameters of biological fluids in dermatitis herpetiformis Duhring. Russian Journal of Skin and Venereal Diseases. 2012;15(4):11–15. (In Russ.) https://doi.org/10.17816/dv42731.

47. Wacklin P., Kaukinen K., Tuovinen E., Collin P., Lindfors K., Partanen J. et al. The duodenal microbiota composition of adult celiac disease patients is associated with the clinical manifestation of the disease. Inflamm Bowel Dis. 2013;19(5):934–941. https://doi.org/10.1097/MIB.0b013e31828029a9.

48. Opryatin L.A. Celiac disease in children with skin pathology: a multidisciplinary problem. Current Pediatrics. 2020;23(6):407–408. (In Russ.) Available at: https://www.medlit.ru/journalsview/pediatrics/view/journal/2020/issue-6/1129-celiakiya-u-detey-s-patologiey-kozhi-multidisciplinarnaya-problema/.

49. Paek S.Y., Steinberg S.M., Katz S.I. Remission in dermatitis herpetiformis: a cohort study. Arch Dermatol. 2011;147(3):301–305. https://doi.org/10.1001/archdermatol.2010.336.

50. Grainge M.J., West J., Solaymani-Dodaran M., Card T.R., Logan R.F. The longterm risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort study. Aliment Pharmacol Ther. 2012;35(6):730–739. https://doi.org/10.1111/j.1365-2036.2012.04998.x.

51. Hervonen K., Salmi T.T., Ilus T., Paasikivi K., Vornanen M., Laurila K. et al. Dermatitis Herpetiformis Refractory to Gluten-free Dietary Treatment. Acta Derm Venereol. 2016;96(1):82–86. https://doi.org/10.2340/00015555-2184.

52. Makharia G.K. Current and emerging therapy for celiac disease. Front Med (Lausanne). 2014;1:6. https://doi.org/10.3389/fmed.2014.00006.

53. Daveson A.J.M., Ee H.C., Andrews J.M., King T., Goldstein K.E., Dzuris J.L. et al. Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. EBioMedicine. 2017;26:78–90. https://doi.org/10.1016/j.ebiom.2017.11.018.

54. Karamova A.E., Znamenskaya L.F., Chikin V.V. Federal clinical guidelines for the management of patients with dermatitis herpetiformis. Moscow; 2015. 13 p. (In Russ.) Available at: https://www.cnikvi.ru/docs/clinic_recs/bolezni-kozhi-i-pridatkov-kozhi/Дерматит герпетиформный.doc.

55. Agafonova E.E., Butkalyuk A.E., Melnichenko O.O., Korsunskaya I.M. Approaches to the therapy of dermatitis herpetiformis Duhring. Effective Pharmacotherapy. 2012;(2):38–41. (In Russ.) Available at: https://umedp.ru/upload/iblock/e4a/e4a76db0f999acdde1d5290f901cf237.pdf.

56. Burbidge T., Haber R.M. Topical Dapsone 5% Gel as an Effective Therapy in Dermatitis Herpetiformis. J Cutan Med Surg. 2016;20(6):600–601. https://doi.org/10.1177/1203475416651053.

57. Albers L.N., Zone J.J., Stoff B.K., Feldman R.J. Rituximab Treatment for Recalcitrant Dermatitis Herpetiformis. JAMA Dermatol. 2017;(3):315–318. https://doi.org/10.1001/jamadermatol.2016.4676.

58. Nevozinskaya Z.A., Denisova E.V., Sakaniia L.R., Guseva S.D., Korsunskaya I.M.Dermatitis herpetiformis Duhring: a guide for the practitioner. Consilium Medicum. Dermatology (Suppl.). 2016;(1):16–17. (In Russ.) Available at: https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2016/derma2016_pril/derma2016_1_pril/gerpetiformnyy-dermatit-dyuringa-v-pomoshch-praktikuyushchemuvrachu/.

59. Żebrowska A., Woźniacka A., Juczyńska K., Ociepa K., Waszczykowska E., Szymczak I., Pawliczak R. Correlation between IL36α and IL17 and Activity of the Disease in Selected Autoimmune Blistering Diseases. Mediators Inflamm. 2017;8980534. https://doi.org/10.1155/2017/8980534.

60. Leonard M.M., Sapone A., Catassi C., Fasano A. Celiac Disease and Nonceliac Gluten Sensitivity: A Review. JAMA. 2017;318(7):647–656. https://doi.org/10.1001/jama.2017.9730.